ORTHO TRI-CYCLEN LO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ortho Tri-cyclen Lo, and what generic alternatives are available?
Ortho Tri-cyclen Lo is a drug marketed by Janssen Pharms and is included in one NDA.
The generic ingredient in ORTHO TRI-CYCLEN LO is ethinyl estradiol; norgestimate. There are twenty-six drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norgestimate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ORTHO TRI-CYCLEN LO?
- What are the global sales for ORTHO TRI-CYCLEN LO?
- What is Average Wholesale Price for ORTHO TRI-CYCLEN LO?
Summary for ORTHO TRI-CYCLEN LO
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ORTHO TRI-CYCLEN LO |
US Patents and Regulatory Information for ORTHO TRI-CYCLEN LO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Pharms | ORTHO TRI-CYCLEN LO | ethinyl estradiol; norgestimate | TABLET;ORAL-28 | 021241-001 | Aug 22, 2002 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ORTHO TRI-CYCLEN LO
See the table below for patents covering ORTHO TRI-CYCLEN LO around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 1226221 | ANTI-PROGRESTATIF TRIPHASE POUR ADMINISTRATION PAR VOIE ORALE (TRIPHASIC ORAL CONTRACEPTIVE) | ⤷ Start Trial |
| Argentina | 028809 | UN METODO ANTICONCEPTIVO Y UNA UNIDAD ANTICONCEPTIVA ORAL TRIFASICA | ⤷ Start Trial |
| Argentina | 034541 | PIRROLIDINAS Y PIPERIDINAS NEUROTROFAS Y COMPOSICIONES FARMACEUTICAS Y EL USO DE LAS MISMAS PARA PREPARAR UN MEDICAMENTO | ⤷ Start Trial |
| Austria | 318605 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ORTHO TRI-CYCLEN LO
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1453521 | 93156 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211 |
| 1380301 | 2009C/007 | Belgium | ⤷ Start Trial | PRODUCT NAME: DROSPIRENONE-ETHINYLESTRADIOL; AUTHORISATION NUMBER AND DATE: BE321386 20080811 |
| 0398460 | C300221 | Netherlands | ⤷ Start Trial | PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307 |
| 1214076 | C01214076/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch